| Neonatal infection: antibiotics for prevention and treatment | NG195 | | |
| Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity | TA1152 | | |
| Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment | TA1153 | | |
| Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal) | TA1154 | | |
| Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer | TA1150 | | |
| Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal) | TA1151 | | |
| Acne vulgaris: management | NG198 | | |
| Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma | TA1149 | | |
| Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over | TA1147 | | |
| Sodium zirconium cyclosilicate for treating hyperkalaemia | TA1148 | | |
| Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors | TA1146 | | |
| Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma | TA1145 | | |
| Ovarian cancer: recognition and initial management | CG122 | | |
| Menopause: identification and management | NG23 | | |
| Suspected cancer: recognition and referral | NG12 | | |
| Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal) | TA1144 | | |
| Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause | TA1143 | | |
| Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils | TA1142 | | |
| Fetal monitoring in labour | NG229 | | |
| Artificial intelligence (AI) technologies to help detect or characterise colorectal polyps | HTG773 | | |
| Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over | TA1140 | | |
| Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal) | TA1141 | | |
| Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment | TA1139 | | |
| Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer | TA1138 | | |
| Hypertension in adults: diagnosis and management | NG136 | | |
| Blood transfusion | NG24 | | |
| Molnupiravir for treating COVID-19 | TA1056 | | |
| Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 | TA878 | | |
| Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer | TA1136 | | |
| Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) | TA1137 | | |
| Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal) | TA1135 | | |
| Type 2 diabetes in adults: management | NG28 | | |
| Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma | TA1133 | | |
| Dupilumab for treating severe chronic rhinosinusitis with nasal polyps | TA1134 | | |
| Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal) | TA1132 | | |
| Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA1129 | | |
| Obinutuzumab with mycophenolate mofetil for treating lupus nephritis | TA1131 | | |
| Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer | TA1130 | | |
| Pulmonary artery pressure technologies for remote monitoring of chronic heart failure | HTG769 | | |
| Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer | TA1127 | | |
| Targeted-release budesonide for treating primary IgA nephropathy | TA1128 | | |
| Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy | TA1126 | | |
| Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal) | TA1124 | | |
| Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal) | TA1125 | | |
| Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) | TA972 | | |
| Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal) | TA1123 | | |
| Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer | TA1122 | | |
| Acoramidis for treating transthyretin amyloidosis with cardiomyopathy | TA1121 | | |
| Overweight and obesity management | NG246 | | |
| Avelumab with axitinib for untreated advanced renal cell carcinoma | TA1120 | | |
| Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) | TA1118 | | |
| Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia | TA1119 | | |
| Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency | TA1117 | | |
| Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia | TA1116 | | |
| Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy | TA1115 | | |
| Child maltreatment: when to suspect maltreatment in under 18s | CG89 | | |
| Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma | TA1113 | | |
| Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1114 | | |
| Suspected sepsis in people aged 16 or over: recognition, assessment and early management | NG253 | | |
| Suspected sepsis in under 16s: recognition, diagnosis and early management | NG254 | | |
| Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early management | NG255 | | |
| Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer | TA1110 | | |
| Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal) | TA1111 | | |
| Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) | TA1112 | | |
| Intrapartum care | NG235 | | |
| Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA1109 | | |
| Cabotegravir for preventing HIV-1 in adults and young people | TA1106 | | |
| Delgocitinib for treating moderate to severe chronic hand eczema | TA1107 | | |
| Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer | TA1108 | | |
| Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) | TA1102 | | |
| Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal) | TA1104 | | |
| Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) | TA1105 | | |
| Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor | TA1103 | | |
| Rehabilitation for chronic neurological disorders including acquired brain injury | NG252 | | |
| Sparsentan for treating primary IgA nephropathy | TA1074 | | |
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over | TA1101 | | |
| Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy | TA1099 | | |
| Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal) | TA1100 | | |
| Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable | TA1098 | | |
| Atopic eczema in under 12s: diagnosis and management | CG57 | | |
| Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable | TA1097 | | |
| Chronic heart failure in adults: diagnosis and management | NG106 | | |
| Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis | TA1096 | | |
| Bipolar disorder: assessment and management | CG185 | | |
| Pneumonia: diagnosis and management | NG250 | | |
| Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management | NG237 | | |
| Tirzepatide for managing overweight and obesity | TA1026 | | |
| Tirzepatide for treating type 2 diabetes | TA924 | | |
| Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over | TA1093 | | |
| Guselkumab for treating moderately to severely active ulcerative colitis | TA1094 | | |
| Guselkumab for previously treated moderately to severely active Crohn's disease | TA1095 | | |
| Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer | TA1092 | | |
| Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments | TA1091 | | |
| Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma | TA1090 | | |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal) | TA1089 | | |
| Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence | TA1086 | | |
| Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen | TA1087 | | |
| Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over | TA1085 | | |
| Cenobamate for treating focal onset seizures in epilepsy | TA753 | | |
| Fruquintinib for previously treated metastatic colorectal cancer | TA1079 | | |
| Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal) | TA1082 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal) | TA1083 | | |
| Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal) | TA1084 | | |
| Mirikizumab for previously treated moderately to severely active Crohn's disease | TA1080 | | |
| Zanubrutinib for treating relapsed or refractory mantle cell lymphoma | TA1081 | | |
| Dapagliflozin for treating chronic kidney disease | TA1075 | | |
| Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal) | TA1076 | | |
| Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA1077 | | |
| Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) | TA1078 | | |
| Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies | TA1073 | | |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1071 | | |
| Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA1072 | | |
| Spesolimab for treating generalised pustular psoriasis flares | TA1070 | | |
| Caesarean birth | NG192 | | |
| Linzagolix for treating symptoms of endometriosis | TA1067 | | |
| Efgartigimod for treating antibody-positive generalised myasthenia gravis | TA1069 | | |
| Headaches in over 12s: diagnosis and management | CG150 | | |
| Somapacitan for treating growth hormone deficiency in people 3 to 17 years | TA1066 | | |
| Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) | TA1068 | | |
| Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA1065 | | |
| Abortion care | NG140 | | |
| Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA1064 | | |
| Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment | TA1063 | | |
| Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor | TA1062 | | |
| Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer | TA1060 | | |
| Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma | TA1059 | | |
| Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal) | TA1061 | | |
| Falls: assessment and prevention in older people and in people 50 and over at higher risk | NG249 | | |
| Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) | TA1058 | | |
| Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA1055 | | |
| Relugolix–estradiol–norethisterone for treating symptoms of endometriosis | TA1057 | | |
| Cladribine for treating active relapsing forms of multiple sclerosis | TA1053 | | |
| Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over | TA1054 | | |
| Early and locally advanced breast cancer: diagnosis and management | NG101 | | |
| Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over | TA1051 | | |
| Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) | TA1052 | | |
| Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over | TA1050 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable | TA1048 | | |
| Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia | TA1049 | | |
| Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma | TA1046 | | |
| Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) | TA1047 | | |
| 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites | TA1045 | | |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA1043 | | |
| Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over | TA1044 | | |
| Advanced breast cancer: diagnosis and treatment | CG81 | | |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA1042 | | |
| Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer | TA1041 | | |
| Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over | TA1033 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over | TA1038 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over | TA1039 | | |
| Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy | TA1040 | | |
| Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment | TA1036 | | |
| Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1037 | | |
| Epilepsies in children, young people and adults | NG217 | | |
| Gambling-related harms: identification, assessment and management | NG248 | | |
| Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease | TA1035 | | |
| Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours | TA1034 | | |
| Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) | TA1032 | | |
| Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over | TA1031 | | |
| Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) | TA1028 | | |
| Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) | TA1029 | | |
| Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1030 | | |
| Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |
| Tebentafusp for treating advanced uveal melanoma | TA1027 | | |
| Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome | HTG735 | | |
| Ublituximab for treating relapsing multiple sclerosis | TA1025 | | |
| Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1023 | | |
| Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal) | TA1024 | | |
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA1021 | | |
| Bevacizumab gamma for treating wet age-related macular degeneration | TA1022 | | |
| Asthma pathway (BTS, NICE, SIGN) | NG244 | | |
| Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | NG245 | | |
| Eplontersen for treating hereditary transthyretin-related amyloidosis | TA1020 | | |
| Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1017 | | |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA1018 | | |
| Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over | TA1019 | | |
| Elafibranor for previously treated primary biliary cholangitis | TA1016 | | |
| Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer | TA1014 | | |
| Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1015 | | |
| Endometriosis: diagnosis and management | NG73 | | |
| Avapritinib for treating advanced systemic mastocytosis | TA1012 | | |
| Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices | HTG730 | | |
| Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria | TA1010 | | |
| Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia | TA1013 | | |
| Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) | HTG729 | | |
| Acute kidney injury: prevention, detection and management | NG148 | | |
| Belzutifan for treating tumours associated with von Hippel-Lindau disease | TA1011 | | |
| Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension | TA1009 | | |
| Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments | TA1008 | | |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA1007 | | |
| Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) | TA1006 | | |
| Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion | TA1004 | | |
| Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA1005 | | |
| Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over | TA1002 | | |
| Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over | TA1003 | | |
| Iptacopan for treating paroxysmal nocturnal haemoglobinuria | TA1000 | | |
| Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment | TA1001 | | |
| Vibegron for treating symptoms of overactive bladder syndrome | TA999 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma | TA997 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
| Adrenal insufficiency: identification and management | NG243 | | |
| Risankizumab for treating moderately to severely active ulcerative colitis | TA998 | | |
| Relugolix for treating hormone-sensitive prostate cancer | TA995 | | |
| Linzagolix for treating moderate to severe symptoms of uterine fibroids | TA996 | | |
| Diabetic retinopathy: management and monitoring | NG242 | | |
| Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) | TA994 | | |
| Abaloparatide for treating osteoporosis after menopause | TA991 | | |
| Burosumab for treating X-linked hypophosphataemia in adults | TA993 | | |
| CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack | HTG724 | | |
| Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy | TA992 | | |
| Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis | TA988 | | |
| Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B | TA989 | | |
| Tenecteplase for treating acute ischaemic stroke | TA990 | | |
| Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA986 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) | TA987 | | |
| Selective internal radiation therapies for treating hepatocellular carcinoma | TA688 | | |
| Tafamidis for treating transthyretin amyloidosis with cardiomyopathy | TA984 | | |
| Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) | TA982 | | |
| Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma | TA983 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) | TA980 | | |
| Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation | TA979 | | |
| Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA976 | | |
| Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over | TA977 | | |
| Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) | TA978 | | |
| Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis | TA312 | | |
| Natalizumab for treating rapidly evolving severe relapsing–remitting multiple sclerosis | TA127 | | |
| Cladribine for treating relapsing–remitting multiple sclerosis | TA616 | | |
| Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion | TA283 | | |
| Ranibizumab for treating choroidal neovascularisation associated with pathological myopia | TA298 | | |
| Ranibizumab and pegaptanib for the treatment of age-related macular degeneration | TA155 | | |
| Atogepant for preventing migraine | TA973 | | |
| Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma | TA974 | | |
| Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under | TA975 | | |
| Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer | HTG719 | | |
| Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments | TA970 | | |
| Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | TA971 | | |
| Artificial intelligence (AI)-derived software to help clinical decision making in stroke | HTG708 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | TA540 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over | TA967 | | |
| Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) | TA969 | | |
| Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA968 | | |
| Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) | TA966 | | |
| Cabozantinib with nivolumab for untreated advanced renal cell carcinoma | TA964 | | |
| Twin and triplet pregnancy | NG137 | | |
| Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) | TA961 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA962 | | |
| Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) | TA965 | | |
| Ritlecitinib for treating severe alopecia areata in people 12 years and over | TA958 | | |
| Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis | TA959 | | |
| Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) | TA960 | | |
| Ovarian cancer: identifying and managing familial and genetic risk | NG241 | | |
| Momelotinib for treating myelofibrosis-related splenomegaly or symptoms | TA957 | | |
| Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management | NG240 | | |
| Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema | TA953 | | |
| Dupilumab for treating moderate to severe prurigo nodularis | TA955 | | |
| Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over | TA956 | | |
| Lung cancer: diagnosis and management | NG122 | | |
| Vitamin B12 deficiency in over 16s: diagnosis and management | NG239 | | |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA954 | | |
| Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations | TA952 | | |
| Tuberculosis | NG33 | | |
| Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over | TA949 | | |
| Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over | TA950 | | |
| Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | | |
| Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments | TA947 | | |
| Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 | | |
| Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) | TA945 | | |
| Devices for remote monitoring of Parkinson's disease | HTG657 | | |
| Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | | |
| Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | | |
| Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) | TA940 | | |
| Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) | TA941 | | |
| Empagliflozin for treating chronic kidney disease | TA942 | | |
| Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | | |
| Risdiplam for treating spinal muscular atrophy | TA755 | | |
| Cardiovascular disease: risk assessment and reduction, including lipid modification | NG238 | | |
| Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | TA939 | | |
| Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) | TA938 | | |
| Secukinumab for treating moderate to severe hidradenitis suppurativa | TA935 | | |
| Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) | TA936 | | |
| Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) | TA933 | | |
| Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms | TA934 | | |
| Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) | TA932 | | |
| Zanubrutinib for treating chronic lymphocytic leukaemia | TA931 | | |
| Transient loss of consciousness ('blackouts') in over 16s | CG109 | | |
| Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments | TA930 | | |
| Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | CG164 | | |
| Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine | TA928 | | |
| Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA929 | | |
| Jaundice in newborn babies under 28 days | CG98 | | |
| Ranibizumab for treating diabetic macular oedema | TA274 | | |
| Mirikizumab for treating moderately to severely active ulcerative colitis | TA925 | | |
| Baricitinib for treating severe alopecia areata | TA926 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable | TA917 | | |
| Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) | TA923 | | |
| Stroke rehabilitation in adults | NG236 | | |
| Rimegepant for treating migraine | TA919 | | |
| Tofacitinib for treating active ankylosing spondylitis | TA920 | | |
| Ruxolitinib for treating polycythaemia vera | TA921 | | |
| Daridorexant for treating long-term insomnia | TA922 | | |
| Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA927 | | |
| Thyroid disease: assessment and management | NG145 | | |
| Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA918 | | |
| Pegunigalsidase alfa for treating Fabry disease | TA915 | | |
| Bimekizumab for treating active psoriatic arthritis | TA916 | | |
| Urinary incontinence in neurological disease: assessment and management | CG148 | | |
| Suspected neurological conditions: recognition and referral | NG127 | | |
| Hearing loss in adults: assessment and management | NG98 | | |
| Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency | TA914 | | |
| Cirrhosis in over 16s: assessment and management | NG50 | | |
| Spinal metastases and metastatic spinal cord compression | NG234 | | |
| Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy | TA913 | | |
| Semaglutide for managing overweight and obesity | TA875 | | |
| Otitis media with effusion in under 12s | NG233 | | |
| Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care | HTG690 | | |
| Ectopic pregnancy and miscarriage: diagnosis and initial management | NG126 | | |
| Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease | TA912 | | |
| Venous thromboembolic diseases: diagnosis, management and thrombophilia testing | NG158 | | |
| Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | TA911 | | |
| Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) | TA910 | | |
| Artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images | HTG687 | | |
| Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy | TA908 | | |
| Rimegepant for preventing migraine | TA906 | | |
| Oesophago-gastric cancer: assessment and management in adults | NG83 | | |
| Deucravacitinib for treating moderate to severe plaque psoriasis | TA907 | | |
| Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA902 | | |
| Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer | TA903 | | |
| Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer | TA904 | | |
| Upadacitinib for previously treated moderately to severely active Crohn's disease | TA905 | | |
| Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) | TA901 | | |
| Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer | TA898 | | |
| Tixagevimab plus cilgavimab for preventing COVID-19 | TA900 | | |
| FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care | HTG682 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over | TA893 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma | TA894 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | TA895 | | |
| Bulevirtide for treating chronic hepatitis D | TA896 | | |
| Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma | TA897 | | |
| Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) | TA899 | | |
| Transperineal biopsy for diagnosing prostate cancer | HTG680 | | |
| Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia | TA891 | | |
| Mosunetuzumab for treating relapsed or refractory follicular lymphoma | TA892 | | |
| Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers | HTG677 | | |
| MRI fusion biopsy systems for diagnosing prostate cancer | HTG678 | | |
| Head injury: assessment and early management | NG232 | | |
| Risankizumab for previously treated moderately to severely active Crohn's disease | TA888 | | |
| Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA889 | | |
| Difelikefalin for treating pruritus in people having haemodialysis | TA890 | | |
| Diabetes (type 1 and type 2) in children and young people: diagnosis and management | NG18 | | |
| Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | TA886 | | |
| Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | TA887 | | |
| Voclosporin with mycophenolate mofetil for treating lupus nephritis | TA882 | | |
| Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma | TA883 | | |
| Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) | TA884 | | |
| Metastatic malignant disease of unknown primary origin in adults: diagnosis and management | CG104 | | |
| Tezepelumab for treating severe asthma | TA880 | | |
| Hypertension in pregnancy: diagnosis and management | NG133 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) | TA879 | | |
| Finerenone for treating chronic kidney disease in type 2 diabetes | TA877 | | |
| Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer | TA876 | | |
| Eptinezumab for preventing migraine | TA871 | | |
| Cannabidiol for treating seizures caused by tuberous sclerosis complex | TA873 | | |
| Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | TA874 | | |
| Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | TA872 | | |
| Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | TA870 | | |
| Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) | TA867 | | |
| Vutrisiran for treating hereditary transthyretin-related amyloidosis | TA868 | | |
| Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management | NG231 | | |
| Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | TA865 | | |
| Regorafenib for previously treated metastatic colorectal cancer | TA866 | | |
| Upadacitinib for treating active non-radiographic axial spondyloarthritis | TA861 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | | |
| Somatrogon for treating growth disturbance in children and young people aged 3 years and over | TA863 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted | TA864 | | |
| Delirium: prevention, diagnosis and management in hospital and long-term care | CG103 | | |
| Maribavir for treating refractory cytomegalovirus infection after transplant | TA860 | | |
| Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) | TA859 | | |
| MRI-based technologies for assessing non-alcoholic fatty liver disease | HTG655 | | |
| Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma | TA857 | | |
| Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | TA858 | | |
| Hip fracture: management | CG124 | | |
| Upadacitinib for treating moderately to severely active ulcerative colitis | TA856 | | |
| Thyroid cancer: assessment and management | NG230 | | |
| Avatrombopag for treating primary chronic immune thrombocytopenia | TA853 | | |
| Cabozantinib for previously treated advanced hepatocellular carcinoma | TA849 | | |
| Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy | TA850 | | |
| Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | | |
| Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | | |
| Esketamine nasal spray for treatment-resistant depression | TA854 | | |
| Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) | TA848 | | |
| Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) | TA845 | | |
| Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) | TA846 | | |
| Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA847 | | |
| Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) | TA843 | | |
| Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) | TA844 | | |
| Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management | NG228 | | |
| Fractures (complex): assessment and management | NG37 | | |
| Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA841 | | |
| Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) | TA842 | | |
| Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids
(terminated appraisal) | TA840 | | |
| Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) | TA838 | | |
| Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA836 | | |
| Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | TA837 | | |
| Osteoarthritis in over 16s: diagnosis and management | NG226 | | |
| Pembrolizumab for adjuvant treatment of renal cell carcinoma | TA830 | | |
| Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | TA832 | | |
| Zanubrutinib for treating Waldenstrom's macroglobulinaemia | TA833 | | |
| Fostamatinib for treating refractory chronic immune thrombocytopenia | TA835 | | |
| Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy | TA827 | | |
| Ozanimod for treating moderately to severely active ulcerative colitis | TA828 | | |
| Upadacitinib for treating active ankylosing spondylitis | TA829 | | |
| Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis | TA825 | | |
| Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) | TA826 | | |
| Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas | CG118 | | |
| Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) | TA822 | | |
| Dexamethasone intravitreal implant for treating diabetic macular oedema | TA824 | | |
| Self-harm: assessment, management and preventing recurrence | NG225 | | |
| Brolucizumab for treating diabetic macular oedema | TA820 | | |
| Avalglucosidase alfa for treating Pompe disease | TA821 | | |
| Type 1 diabetes in adults: diagnosis and management | NG17 | | |
| Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | TA818 | | |
| Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | | |
| Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA815 | | |
| Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | | |
| Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | | |
| Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer | TA812 | | |
| Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | TA813 | | |
| Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis | TA814 | | |
| Urinary tract infection in under 16s: diagnosis and management | NG224 | | |
| Melanoma: assessment and management | NG14 | | |
| PLGF-based testing to help diagnose suspected preterm pre-eclampsia | HTG630 | | |
| Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) | TA811 | | |
| Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease | TA809 | | |
| Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | | |
| Belimumab for treating lupus nephritis (terminated appraisal) | TA806 | | |
| Roxadustat for treating symptomatic anaemia in chronic kidney disease | TA807 | | |
| Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA803 | | |
| Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides | TA805 | | |
| Fenfluramine for treating seizures associated with Dravet syndrome | TA808 | | |
| Teduglutide for treating short bowel syndrome | TA804 | | |
| Depression in adults: treatment and management | NG222 | | |
| Faricimab for treating diabetic macular oedema | TA799 | | |
| Faricimab for treating wet age-related macular degeneration | TA800 | | |
| Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | | |
| Cemiplimab for treating advanced cutaneous squamous cell carcinoma | TA802 | | |
| Multiple sclerosis in adults: management | NG220 | | |
| Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation | TA798 | | |
| Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | | |
| Venetoclax for treating chronic lymphocytic leukaemia | TA796 | | |
| Preterm labour and birth | NG25 | | |
| Gout: diagnosis and management | NG219 | | |
| Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) | TA793 | | |
| Diroximel fumarate for treating relapsing–remitting multiple sclerosis | TA794 | | |
| Ibrutinib for treating Waldenstrom's macroglobulinaemia | TA795 | | |
| Filgotinib for treating moderately to severely active ulcerative colitis | TA792 | | |
| TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) | TA790 | | |
| Romosozumab for treating severe osteoporosis | TA791 | | |
| Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations | TA789 | | |
| Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy | TA788 | | |
| Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies | TA786 | | |
| Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA787 | | |
| Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults | NG215 | | |
| Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | TA784 | | |
| Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) | TA785 | | |
| Stroke and transient ischaemic attack in over 16s: diagnosis and initial management | NG128 | | |
| Daratumumab monotherapy for treating relapsed and refractory multiple myeloma | TA783 | | |
| Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) | HTG619 | | |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer | TA781 | | |
| Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) | TA782 | | |
| Nivolumab with ipilimumab for untreated advanced renal cell carcinoma | TA780 | | |
| Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA779 | | |
| Empagliflozin for treating chronic heart failure with reduced ejection fraction | TA773 | | |
| Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA774 | | |
| Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA776 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA777 | | |
| Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria | TA778 | | |
| PredictSURE IBD and IBDX to guide treatment of Crohn's disease | HTG610 | | |
| EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules | HTG611 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies | TA772 | | |
| Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer | TA770 | | |
| Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) | TA771 | | |
| Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | TA766 | | |
| Ponesimod for treating relapsing–remitting multiple sclerosis | TA767 | | |
| Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA768 | | |
| Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable | TA763 | | |
| Fremanezumab for preventing migraine | TA764 | | |
| Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA765 | | |
| Glaucoma: diagnosis and management | NG81 | | |
| Rehabilitation after traumatic injury | NG211 | | |
| Cabotegravir with rilpivirine for treating HIV-1 | TA757 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy | TA758 | | |
| Prostate cancer: diagnosis and management | NG131 | | |
| Colorectal cancer | NG151 | | |
| Belimumab for treating active autoantibody-positive systemic lupus erythematosus | TA752 | | |
| Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome | TA754 | | |
| Pelvic floor dysfunction: prevention and non-surgical management | NG210 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | | |
| Dupilumab for treating severe asthma with type 2 inflammation | TA751 | | |
| Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders | TA748 | | |
| Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) | TA749 | | |
| Fever in under 5s: assessment and initial management | NG143 | | |
| Chronic kidney disease: assessment and management | NG203 | | |
| Acute heart failure: diagnosis and management | CG187 | | |
| Heart valve disease presenting in adults: investigation and management | NG208 | | |
| SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea | HTG598 | | |
| Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | | |
| Nintedanib for treating progressive fibrosing interstitial lung diseases | TA747 | | |
| Upadacitinib for treating moderate rheumatoid arthritis | TA744 | | |
| NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) | TA745 | | |
| Inducing labour | NG207 | | |
| Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management | NG206 | | |
| Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | | |
| Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | | |
| Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | | |
| Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy | TA736 | | |
| Berotralstat for preventing recurrent attacks of hereditary angioedema | TA738 | | |
| Tofacitinib for treating juvenile idiopathic arthritis | TA735 | | |
| Secukinumab for treating moderate to severe plaque psoriasis in children and young people | TA734 | | |
| Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) | TA732 | | |
| Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA733 | | |
| Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) | TA730 | | |
| Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) | TA731 | | |
| Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA726 | | |
| Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA727 | | |
| Midostaurin for treating advanced systemic mastocytosis | TA728 | | |
| Sapropterin for treating hyperphenylalaninaemia in phenylketonuria | TA729 | | |
| Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | | |
| Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer | TA724 | | |
| Bimekizumab for treating moderate to severe plaque psoriasis | TA723 | | |
| Babies, children and young people's experience of healthcare | NG204 | | |
| Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA722 | | |
| Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s | NG202 | | |
| Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome | TA139 | | |
| Antenatal care | NG201 | | |
| Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | TA720 | | |
| Bronchiolitis in children: diagnosis and management | NG9 | | |
| Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | | |
| Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) | TA717 | | |
| Ixekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA718 | | |
| Secukinumab for treating active non-radiographic axial spondyloarthritis | TA719 | | |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA714 | | |
| Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | | |
| Enzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | | |
| Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy | TA713 | | |
| Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | TA249 | | |
| Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | TA256 | | |
| Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA275 | | |
| Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA355 | | |
| Atrial fibrillation: diagnosis and management | NG196 | | |
| Ravulizumab for treating atypical haemolytic uraemic syndrome | TA710 | | |
| Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis | TA708 | | |
| Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | | |
| Patient experience in adult NHS services: improving the experience of care for people using adult NHS services | CG138 | | |
| Shared decision making | NG197 | | |
| Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | | |
| Autism spectrum disorder in adults: diagnosis and management | CG142 | | |
| Autism spectrum disorder in under 19s: support and management | CG170 | | |
| Ozanimod for treating relapsing–remitting multiple sclerosis | TA706 | | |
| Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer | TA705 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | | |
| Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) | TA702 | | |
| Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) | TA703 | | |
| Heavy menstrual bleeding: assessment and management | NG88 | | |
| Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) | TA701 | | |
| Ravulizumab for treating paroxysmal nocturnal haemoglobinuria | TA698 | | |
| Ofatumumab for treating relapsing multiple sclerosis | TA699 | | |
| Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA692 | | |
| Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA694 | | |
| Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma | TA695 | | |
| Acalabrutinib for treating chronic lymphocytic leukaemia | TA689 | | |
| Avelumab for treating metastatic Merkel cell carcinoma | TA517 | | |
| Avelumab for untreated metastatic Merkel cell carcinoma | TA691 | | |
| Postnatal care | NG194 | | |
| Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain | NG193 | | |
| Anakinra for treating Still's disease | TA685 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA686 | | |
| Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA687 | | |
| Cannabis-based medicinal products | NG144 | | |
| QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography | HTG571 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease | TA684 | | |
| Erenumab for preventing migraine | TA682 | | |
| Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer | TA683 | | |
| Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma | TA680 | | |
| Baricitinib for treating moderate to severe atopic dermatitis | TA681 | | |
| Filgotinib for treating moderate to severe rheumatoid arthritis | TA676 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma | TA677 | | |
| Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA678 | | |
| Dapagliflozin for treating chronic heart failure with reduced ejection fraction | TA679 | | |
| Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | TA674 | | |
| Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) | TA675 | | |
| Trabectedin for the treatment of advanced soft tissue sarcoma | TA185 | | |
| Mepolizumab for treating severe eosinophilic asthma | TA671 | | |
| Brolucizumab for treating wet age-related macular degeneration | TA672 | | |
| Brain tumours (primary) and brain metastases in over 16s | NG99 | | |
| Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor | TA670 | | |
| Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer | TA668 | | |
| Pancreatitis | NG104 | | |
| Eating disorders: recognition and treatment | NG69 | | |
| Diabetes in pregnancy: management from preconception to the postnatal period | NG3 | | |
| Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma | TA666 | | |
| Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura | TA667 | | |
| Peripheral arterial disease: diagnosis and management | CG147 | | |
| Low back pain and sciatica in over 16s: assessment and management | NG59 | | |
| Liraglutide for managing overweight and obesity | TA664 | | |
| Upadacitinib for treating severe rheumatoid arthritis | TA665 | | |
| Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) | TA662 | | |
| Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer | TA660 | | |
| Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma | TA661 | | |
| Acute coronary syndromes | NG185 | | |
| Drug-eluting stents for the treatment of coronary artery disease | TA152 | | |
| Guidance on the use of coronary artery stents | TA71 | | |
| Siponimod for treating secondary progressive multiple sclerosis | TA656 | | |
| Carfilzomib for previously treated multiple myeloma | TA657 | | |
| Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma | TA658 | | |
| Galcanezumab for preventing migraine | TA659 | | |
| Testing strategies for Lynch syndrome in people with endometrial cancer | HTG557 | | |
| Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy | TA655 | | |
| Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer | TA653 | | |
| Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA654 | | |
| Rheumatoid arthritis in adults: management | NG100 | | |
| Pembrolizumab with axitinib for untreated advanced renal cell carcinoma | TA650 | | |
| Naldemedine for treating opioid-induced constipation | TA651 | | |
| Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma | TA649 | | |
| Neuropathic pain in adults: pharmacological management in non-specialist settings | CG173 | | |
| Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke | HTG553 | | |
| Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) | TA646 | | |
| Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) | TA647 | | |
| High-sensitivity troponin tests for the early rule out of NSTEMI | HTG552 | | |
| Anaphylaxis: assessment and referral after emergency treatment | CG134 | | |
| Perioperative care in adults | NG180 | | |
| Rehabilitation for adults with complex psychosis | NG181 | | |
| Surgical site infections: prevention and treatment | NG125 | | |
| Gilteritinib for treating relapsed or refractory acute myeloid leukaemia | TA642 | | |
| Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer | TA643 | | |
| Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma | TA641 | | |
| Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant | TA640 | | |
| Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA638 | | |
| Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | TA639 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA634 | | |
| Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) | TA635 | | |
| Eculizumab for treating refractory myasthenia gravis (terminated appraisal) | TA636 | | |
| Ranibizumab for treating diabetic retinopathy (terminated appraisal) | TA637 | | |
| Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA626 | | |
| Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) | HTG544 | | |
| Ustekinumab for treating moderately to severely active ulcerative colitis | TA633 | | |
| Generalised anxiety disorder and panic disorder in adults: management | CG113 | | |
| Intravenous fluid therapy in children and young people in hospital | NG29 | | |
| Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer | TA632 | | |
| Joint replacement (primary): hip, knee and shoulder | NG157 | | |
| Larotrectinib for treating NTRK fusion-positive solid tumours | TA630 | | |
| Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer | TA628 | | |
| Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab | TA629 | | |
| Lenalidomide with rituximab for previously treated follicular lymphoma | TA627 | | |
| Abdominal aortic aneurysm: diagnosis and management | NG156 | | |
| Tinnitus: assessment and management | NG155 | | |
| Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) | TA625 | | |
| Neonatal parenteral nutrition | NG154 | | |
| SepsiTest assay for rapidly identifying bloodstream bacteria and fungi | HTG400 | | |
| Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis | TA624 | | |
| Patiromer for treating hyperkalaemia | TA623 | | |
| Antenatal and postnatal mental health: clinical management and service guidance | CG192 | | |
| Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) | TA618 | | |
| Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA617 | | |
| Cannabidiol with clobazam for treating seizures associated with Dravet syndrome | TA614 | | |
| Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome | TA615 | | |
| Diverticular disease: diagnosis and management | NG147 | | |
| Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab | TA612 | | |
| Rapid tests for group A streptococcal infections in people with a sore throat | HTG531 | | |
| Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast | HTG530 | | |
| Pentosan polysulfate sodium for treating bladder pain syndrome | TA610 | | |
| Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) | TA608 | | |
| Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) | TA609 | | |
| Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management | CG184 | | |
| Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease | TA607 | | |
| End of life care for adults: service delivery | NG142 | | |
| Lanadelumab for preventing recurrent attacks of hereditary angioedema | TA606 | | |
| Diabetic foot problems: prevention and management | NG19 | | |
| Gastro-oesophageal reflux disease in children and young people: diagnosis and management | NG1 | | |
| Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea | TA605 | | |
| Familial hypercholesterolaemia: identification and management | CG71 | | |
| Idelalisib for treating refractory follicular lymphoma | TA604 | | |
| Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA602 | | |
| Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA603 | | |
| Attention deficit hyperactivity disorder: diagnosis and management | NG87 | | |
| Benralizumab for treating severe eosinophilic asthma | TA565 | | |
| Risankizumab for treating moderate to severe plaque psoriasis | TA596 | | |
| Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA595 | | |
| Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism | NG89 | | |
| Letermovir for preventing cytomegalovirus disease after a stem cell transplant | TA591 | | |
| Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis | TA590 | | |
| Chronic obstructive pulmonary disease in over 16s: diagnosis and management | NG115 | | |
| End of life care for infants, children and young people with life-limiting conditions: planning and management | NG61 | | |
| Nusinersen for treating spinal muscular atrophy | TA588 | | |
| Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity | TA589 | | |
| Motor neurone disease: assessment and management | NG42 | | |
| Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis | HTG521 | | |
| Bisphosphonates for treating osteoporosis | TA464 | | |
| Long-acting reversible contraception | CG30 | | |
| Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies | TA171 | | |
| Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality | TA322 | | |
| Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib | TA586 | | |
| Lenalidomide plus dexamethasone for previously untreated multiple myeloma | TA587 | | |
| Depression in children and young people: identification and management | NG134 | | |
| Urinary incontinence and pelvic organ prolapse in women: management | NG123 | | |
| Ocrelizumab for treating primary progressive multiple sclerosis | TA585 | | |
| Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes | TA583 | | |
| Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer | TA584 | | |
| Hyperparathyroidism (primary): diagnosis, assessment and initial management | NG132 | | |
| Enzalutamide for hormone-relapsed non-metastatic prostate cancer | TA580 | | |
| Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care | HTG508 | | |
| Crohn's disease: management | NG129 | | |
| Ulcerative colitis: management | NG130 | | |
| Intrapartum care for women with existing medical conditions or obstetric complications and their babies | NG121 | | |
| Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma | TA577 | | |
| Certolizumab pegol for treating moderate to severe plaque psoriasis | TA574 | | |
| Tildrakizumab for treating moderate to severe plaque psoriasis | TA575 | | |
| Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) | TA576 | | |
| Specialist neonatal respiratory care for babies born preterm | NG124 | | |
| Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes | TA572 | | |
| Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer | TA569 | | |
| Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) | TA570 | | |
| Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib | TA571 | | |
| Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) | TA568 | | |
| Cochlear implants for children and adults with severe to profound deafness | TA566 | | |
| Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia | TA561 | | |
| Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma | TA562 | | |
| Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA563 | | |
| Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) | TA560 | | |
| Cerebral palsy in adults | NG119 | | |
| Regorafenib for previously treated advanced hepatocellular carcinoma | TA555 | | |
| Darvadstrocel for treating complex perianal fistulas in Crohn's disease | TA556 | | |
| Renal and ureteric stones: assessment and management | NG118 | | |
| Lenvatinib for untreated advanced hepatocellular carcinoma | TA551 | | |
| Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia | TA552 | | |
| Vandetanib for treating medullary thyroid cancer | TA550 | | |
| Post-traumatic stress disorder | NG116 | | |
| Decitabine for untreated acute myeloid leukaemia (terminated appraisal) | TA548 | | |
| Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) | TA549 | | |
| Tofacitinib for moderately to severely active ulcerative colitis | TA547 | | |
| Padeliporfin for untreated localised prostate cancer | TA546 | | |
| Gemtuzumab ozogamicin for untreated acute myeloid leukaemia | TA545 | | |
| Eltrombopag for treating chronic immune thrombocytopenia | TA293 | | |
| Romiplostim for the treatment of chronic immune thrombocytopenia | TA221 | | |
| Myeloma: diagnosis and management | NG35 | | |
| Lyme disease | NG95 | | |
| Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma | TA544 | | |
| Renal replacement therapy and conservative management | NG107 | | |
| Cabozantinib for untreated advanced renal cell carcinoma | TA542 | | |
| Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA543 | | |
| Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia | TA541 | | |
| Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours | TA539 | | |
| Dinutuximab beta for treating neuroblastoma | TA538 | | |
| Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | | |
| Alectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | | |
| Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA537 | | |
| Dupilumab for treating moderate to severe atopic dermatitis | TA534 | | |
| Ocrelizumab for treating relapsing–remitting multiple sclerosis | TA533 | | |
| Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | TA531 | | |
| Biomarker tests to help diagnose preterm labour in women with intact membranes | HTG476 | | |
| Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy | TA530 | | |
| Beta interferons and glatiramer acetate for treating multiple sclerosis | TA527 | | |
| Dementia: assessment, management and support for people living with dementia and their carers | NG97 | | |
| Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | TA217 | | |
| Guselkumab for treating moderate to severe plaque psoriasis | TA521 | | |
| Midostaurin for untreated acute myeloid leukaemia | TA523 | | |
| Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma | TA524 | | |
| Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA525 | | |
| Arsenic trioxide for treating acute promyelocytic leukaemia | TA526 | | |
| Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over | NG36 | | |
| Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy | TA520 | | |
| Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I | HTG467 | | |
| Tocilizumab for treating giant cell arteritis | TA518 | | |
| Emergency and acute medical care in over 16s: service delivery and organisation | NG94 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen | TA515 | | |
| Cabozantinib for treating medullary thyroid cancer | TA516 | | |
| Tivozanib for treating advanced renal cell carcinoma | TA512 | | |
| Obinutuzumab for untreated advanced follicular lymphoma | TA513 | | |
| Brodalumab for treating moderate to severe plaque psoriasis | TA511 | | |
| Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee | TA508 | | |
| Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer | TA509 | | |
| Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C | TA507 | | |
| Pancreatic cancer in adults: diagnosis and management | NG85 | | |
| Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women | TA160 | | |
| Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women | TA161 | | |
| Pirfenidone for treating idiopathic pulmonary fibrosis | TA504 | | |
| Intrabeam radiotherapy system for adjuvant treatment of early breast cancer | TA501 | | |
| Ibrutinib for treating relapsed or refractory mantle cell lymphoma | TA502 | | |
| Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer | TA503 | | |
| Lenvatinib with everolimus for previously treated advanced renal cell carcinoma | TA498 | | |
| Glecaprevir–pibrentasvir for treating chronic hepatitis C | TA499 | | |
| Ceritinib for untreated ALK-positive non-small-cell lung cancer | TA500 | | |
| Age-related macular degeneration | NG82 | | |
| Golimumab for treating active non-radiographic axial spondyloarthritis | TA497 | | |
| Autism spectrum disorder in under 19s: recognition, referral and diagnosis | CG128 | | |
| Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA495 | | |
| Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA496 | | |
| Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) | HTG353 | | |
| Naltrexone–bupropion for managing overweight and obesity | TA494 | | |
| Vismodegib for treating basal cell carcinoma | TA489 | | |
| Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane | TA458 | | |
| Tests in secondary care to identify people at high risk of ovarian cancer | HTG453 | | |
| Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours | TA488 | | |
| Sarilumab for moderate to severe rheumatoid arthritis | TA485 | | |
| Aflibercept for treating choroidal neovascularisation | TA486 | | |
| Cataracts in adults: management | NG77 | | |
| Cystic fibrosis: diagnosis and management | NG78 | | |
| Hepatitis B (chronic): diagnosis and management | CG165 | | |
| Tofacitinib for moderate to severe rheumatoid arthritis | TA480 | | |
| Immunosuppressive therapy for kidney transplant in adults | TA481 | | |
| Immunosuppressive therapy for kidney transplant in children and young people | TA482 | | |
| Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee | TA477 | | |
| Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma | TA478 | | |
| Reslizumab for treating severe eosinophilic asthma | TA479 | | |
| Faltering growth: recognition and management of faltering growth in children | NG75 | | |
| Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | TA439 | | |
| Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy | TA428 | | |
| Pembrolizumab for advanced melanoma not previously treated with ipilimumab | TA366 | | |
| Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab | TA357 | | |
| Sorafenib for treating advanced hepatocellular carcinoma | TA474 | | |
| Dimethyl fumarate for treating moderate to severe plaque psoriasis | TA475 | | |
| Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | TA476 | | |
| Psoriasis: assessment and management | CG153 | | |
| Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck | TA473 | | |
| Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) | TA468 | | |
| Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) | TA469 | | |
| Holoclar for treating limbal stem cell deficiency after eye burns | TA467 | | |
| Pemetrexed for the maintenance treatment of non-small-cell lung cancer | TA190 | | |
| Developmental follow-up of children and young people born preterm | NG72 | | |
| Cabozantinib for previously treated advanced renal cell carcinoma | TA463 | | |
| Baricitinib for moderate to severe rheumatoid arthritis | TA466 | | |
| Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition | CG32 | | |
| Adalimumab and dexamethasone for treating non-infectious uveitis | TA460 | | |
| Roflumilast for treating chronic obstructive pulmonary disease | TA461 | | |
| Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma | TA462 | | |
| Parkinson's disease in adults | NG71 | | |
| Constipation in children and young people: diagnosis and management | CG99 | | |
| Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people | TA455 | | |
| Ustekinumab for moderately to severely active Crohn's disease after previous treatment | TA456 | | |
| New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners | HTG281 | | |
| Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) | TA452 | | |
| Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) | TA453 | | |
| Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA454 | | |
| Etelcalcetide for treating secondary hyperparathyroidism | TA448 | | |
| Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease | TA449 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia | TA450 | | |
| Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia | TA451 | | |
| Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis | HTG441 | | |
| Spondyloarthritis in over 16s: diagnosis and management | NG65 | | |
| Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA444 | | |
| Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA445 | | |
| Idiopathic pulmonary fibrosis in adults: diagnosis and management | CG163 | | |
| Virtual chromoendoscopy to assess colorectal polyps during colonoscopy | HTG438 | | |
| Intravenous fluid therapy in adults in hospital | CG174 | | |
| Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine | TA440 | | |
| Ixekizumab for treating moderate to severe plaque psoriasis | TA442 | | |
| Obeticholic acid for treating primary biliary cholangitis | TA443 | | |
| Antisocial behaviour and conduct disorders in children and young people: recognition and management | CG158 | | |
| Alcohol-use disorders: diagnosis and management of physical complications | CG100 | | |
| Irritable bowel syndrome in adults: diagnosis and management | CG61 | | |
| Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) | TA240 | | |
| Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | TA438 | | |
| Elotuzumab for previously treated multiple myeloma (terminated appraisal) | TA434 | | |
| Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) | TA435 | | |
| Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) | TA436 | | |
| Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) | TA437 | | |
| Mental health of adults in contact with the criminal justice system | NG66 | | |
| Ustekinumab for treating moderate to severe plaque psoriasis | TA180 | | |
| Ustekinumab for treating active psoriatic arthritis | TA340 | | |
| Molecular testing strategies for Lynch syndrome in people with colorectal cancer | HTG430 | | |
| Everolimus for advanced renal cell carcinoma after previous treatment | TA432 | | |
| Apremilast for treating active psoriatic arthritis | TA433 | | |
| Healthcare-associated infections: prevention and control in primary and community care | CG139 | | |
| Osteoporosis: assessing the risk of fragility fracture | CG146 | | |
| Cerebral palsy in under 25s: assessment and management | NG62 | | |
| Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | TA429 | | |
| Sofosbuvir–velpatasvir for treating chronic hepatitis C | TA430 | | |
| Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib | TA427 | | |
| Organ donation for transplantation: improving donor identification and consent rates for deceased organ donation | CG135 | | |
| Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | TA425 | | |
| Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia | TA426 | | |
| Everolimus with exemestane for treating advanced breast cancer after endocrine therapy | TA421 | | |
| Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA422 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens | TA423 | | |
| Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | TA424 | | |
| Hypothermia: prevention and management in adults having surgery | CG65 | | |
| Ticagrelor for preventing atherothrombotic events after myocardial infarction | TA420 | | |
| Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis | CG95 | | |
| Spasticity in under 19s: management | CG145 | | |
| Dapagliflozin in combination therapy for treating type 2 diabetes | TA288 | | |
| Nivolumab for previously treated advanced renal cell carcinoma | TA417 | | |
| Dapagliflozin in triple therapy for treating type 2 diabetes | TA418 | | |
| Apremilast for treating moderate to severe plaque psoriasis | TA419 | | |
| High-throughput non-invasive prenatal testing for fetal RHD genotype | HTG420 | | |
| Physical health of people in prison | NG57 | | |
| Psychosis and schizophrenia in children and young people: recognition and management | CG155 | | |
| Elbasvir–grazoprevir for treating chronic hepatitis C | TA413 | | |
| Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma | TA414 | | |
| Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor | TA415 | | |
| Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA406 | | |
| Secukinumab for treating active ankylosing spondylitis | TA407 | | |
| Pegaspargase for treating acute lymphoblastic leukaemia | TA408 | | |
| Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | | |
| Talimogene laherparepvec for treating unresectable metastatic melanoma | TA410 | | |
| Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer | TA411 | | |
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | TA412 | | |
| Multimorbidity: clinical assessment and management | NG56 | | |
| Mental health problems in people with learning disabilities: prevention, assessment and management | NG54 | | |
| Stable angina: management | CG126 | | |
| Acute upper gastrointestinal bleeding in over 16s: management | CG141 | | |
| Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel | TA391 | | |
| Bosutinib for previously treated chronic myeloid leukaemia | TA401 | | |
| Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin | TA402 | | |
| Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer | TA403 | | |
| Degarelix for treating advanced hormone-dependent prostate cancer | TA404 | | |
| Trifluridine–tipiracil for previously treated metastatic colorectal cancer | TA405 | | |
| Palliative care for adults: strong opioids for pain relief | CG140 | | |
| Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen | TA259 | | |
| Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts | TA399 | | |
| Nivolumab in combination with ipilimumab for treating advanced melanoma | TA400 | | |
| Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA387 | | |
| Non-Hodgkin's lymphoma: diagnosis and management | NG52 | | |
| Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures | CG64 | | |
| Non-alcoholic fatty liver disease (NAFLD): assessment and management | NG49 | | |
| Adalimumab for treating moderate to severe hidradenitis suppurativa | TA392 | | |
| Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA393 | | |
| Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA394 | | |
| Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer | TA395 | | |
| Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | TA396 | | |
| Haematological cancers: improving outcomes | NG47 | | |
| Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | TA390 | | |
| ImmunoCAP ISAC 112 for multiplex allergen testing | HTG413 | | |
| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer | TA389 | | |
| Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction | TA388 | | |
| Routine preoperative tests for elective surgery | NG45 | | |
| Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis | TA386 | | |
| Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) | TA23 | | |
| Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia | TA385 | | |
| Nivolumab for treating advanced (unresectable or metastatic) melanoma | TA384 | | |
| Fractures (non-complex): assessment and management | NG38 | | |
| Major trauma: assessment and initial management | NG39 | | |
| Major trauma: service delivery | NG40 | | |
| Spinal injury: assessment and initial management | NG41 | | |
| Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) | HTG401 | | |
| TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | | |
| Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA377 | | |
| Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy | TA378 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis | TA379 | | |
| Panobinostat for treating multiple myeloma after at least 2 previous treatments | TA380 | | |
| Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) | TA382 | | |
| Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | | |
| Guidance on the use of imatinib for chronic myeloid leukaemia | TA70 | | |
| Care of dying adults in the last days of life | NG31 | | |
| Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears | TA369 | | |
| Bortezomib for previously untreated mantle cell lymphoma | TA370 | | |
| Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis | TA373 | | |
| Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy | TA374 | | |
| Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care | NG26 | | |
| Vortioxetine for treating major depressive episodes | TA367 | | |
| Ledipasvir–sofosbuvir for treating chronic hepatitis C | TA363 | | |
| Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C | TA365 | | |
| VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions | HTG388 | | |
| Tolvaptan for treating autosomal dominant polycystic kidney disease | TA358 | | |
| Idelalisib for treating chronic lymphocytic leukaemia | TA359 | | |
| Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) | TA362 | | |
| Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) | HTG386 | | |
| Coeliac disease: recognition, assessment and management | NG20 | | |
| Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy | TA352 | | |
| Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) | TA353 | | |
| Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism | TA354 | | |
| Naloxegol for treating opioid‑induced constipation | TA345 | | |
| Aflibercept for treating diabetic macular oedema | TA346 | | |
| Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer | TA347 | | |
| Everolimus for preventing organ rejection in liver transplantation | TA348 | | |
| Secukinumab for treating moderate to severe plaque psoriasis | TA350 | | |
| Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) | TA351 | | |
| Omalizumab for previously treated chronic spontaneous urticaria | TA339 | | |
| Vedolizumab for treating moderately to severely active ulcerative colitis | TA342 | | |
| Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA341 | | |
| Lower urinary tract symptoms in men: management | CG97 | | |
| Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia | TA343 | | |
| Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges | NG11 | | |
| Violence and aggression: short-term management in mental health, health and community settings | NG10 | | |
| Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome | TA335 | | |
| Empagliflozin in combination therapy for treating type 2 diabetes | TA336 | | |
| Rifaximin for preventing episodes of overt hepatic encephalopathy | TA337 | | |
| Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes | NG5 | | |
| Bladder cancer: diagnosis and management | NG2 | | |
| Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | | |
| Sofosbuvir for treating chronic hepatitis C | TA330 | | |
| Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment | TA333 | | |
| Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) | TA334 | | |
| Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma | TA269 | | |
| Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA327 | | |
| Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment | HTG360 | | |
| Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy | TA323 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block | TA324 | | |
| Nalmefene for reducing alcohol consumption in people with alcohol dependence | TA325 | | |
| Imatinib for the adjuvant treatment of gastrointestinal stromal tumours | TA326 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block | TA88 | | |
| Gallstone disease: diagnosis and management | CG188 | | |
| Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma | TA321 | | |
| Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence | CG115 | | |
| Drug allergy: diagnosis and management | CG183 | | |
| Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis | TA320 | | |
| Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) | HTG348 | | |
| Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen | TA316 | | |
| Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes | TA317 | | |
| Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma | TA319 | | |
| Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure | TA314 | | |
| Canagliflozin in combination therapy for treating type 2 diabetes | TA315 | | |
| Teriflunomide for treating relapsing–remitting multiple sclerosis | TA303 | | |
| Pressure ulcers: prevention and management | CG179 | | |
| Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | | |
| Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation | TA311 | | |
| Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis | TA308 | | |
| Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy | TA307 | | |
| Psychosis and schizophrenia in adults: prevention and management | CG178 | | |
| Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip | TA304 | | |
| Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | | |
| Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma | TA306 | | |
| Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C | TA106 | | |
| Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people | TA300 | | |
| Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) | TA302 | | |
| Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C | TA75 | | |
| Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel | HTG320 | | |
| EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer | HTG316 | | |
| Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer | HTG315 | | |
| Pazopanib for the first-line treatment of advanced renal cell carcinoma | TA215 | | |
| Varicose veins: diagnosis and management | CG168 | | |
| Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder | TA292 | | |
| Aflibercept solution for injection for treating wet age‑related macular degeneration | TA294 | | |
| Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | TA287 | | |
| Mirabegron for treating symptoms of overactive bladder | TA290 | | |
| Social anxiety disorder: recognition, assessment and treatment | CG159 | | |
| Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | TA284 | | |
| Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer | TA285 | | |
| Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) | TA286 | | |
| Omalizumab for treating severe persistent allergic asthma | TA278 | | |
| Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures | TA279 | | |
| Antisocial personality disorder: prevention and management | CG77 | | |
| Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) | TA277 | | |
| Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis | TA276 | | |
| Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract | TA272 | | |
| Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | TA273 | | |
| Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma | TA268 | | |
| Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) | TA270 | | |
| Dronedarone for the treatment of non-permanent atrial fibrillation | TA197 | | |
| Mannitol dry powder for inhalation for treating cystic fibrosis | TA266 | | |
| Ivabradine for treating chronic heart failure | TA267 | | |
| Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M | HTG292 | | |
| Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours | TA265 | | |
| Alteplase for treating acute ischaemic stroke | TA264 | | |
| Neutropenic sepsis: prevention and management in people with cancer | CG151 | | |
| SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver | HTG291 | | |
| Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer | TA263 | | |
| Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | TA261 | | |
| Sickle cell disease: managing acute painful episodes in hospital | CG143 | | |
| Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 | TA257 | | |
| Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer | TA258 | | |
| Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | TA260 | | |
| Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis | TA254 | | |
| Tocilizumab for the treatment of rheumatoid arthritis | TA247 | | |
| Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy | TA242 | | |
| Rituximab for the first-line treatment of stage III-IV follicular lymphoma | TA243 | | |
| Apixaban for preventing venous thromboembolism after hip or knee replacement surgery | TA245 | | |
| Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services | CG136 | | |
| Tocilizumab for the treatment of systemic juvenile idiopathic arthritis | TA238 | | |
| Fulvestrant for the treatment of locally advanced or metastatic breast cancer | TA239 | | |
| The EOS 2D/3D imaging system | HTG274 | | |
| Mifamurtide for the treatment of osteosarcoma | TA235 | | |
| Ticagrelor for the treatment of acute coronary syndromes | TA236 | | |
| Bortezomib and thalidomide for the first‑line treatment of multiple myeloma | TA228 | | |
| Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion | TA229 | | |
| Agomelatine for the treatment of major depressive episodes (terminated appraisal) | TA231 | | |
| Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction | TA73 | | |
| Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer | TA227 | | |
| Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs | TA225 | | |
| Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma | TA226 | | |
| Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease | TA223 | | |
| Golimumab for the treatment of psoriatic arthritis | TA220 | | |
| Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings | CG120 | | |
| Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia | TA218 | | |
| Food allergy in under 19s: assessment and diagnosis | CG116 | | |
| Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer | TA214 | | |
| Bendamustine for the first-line treatment of chronic lymphocytic leukaemia | TA216 | | |
| Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | TA213 | | |
| Sedation in under 19s: using sedation for diagnostic and therapeutic procedures | CG112 | | |
| Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events | TA210 | | |
| Prucalopride for the treatment of chronic constipation in women | TA211 | | |
| Trastuzumab for the treatment of HER2-positive metastatic gastric cancer | TA208 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours | TA209 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours | TA86 | | |
| Bedwetting in under 19s | CG111 | | |
| Denosumab for the prevention of osteoporotic fractures in postmenopausal women | TA204 | | |
| Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) | TA206 | | |
| Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA207 | | |
| Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factors | CG110 | | |
| Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C | TA200 | | |
| Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | TA199 | | |
| Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | TA195 | | |
| Capecitabine for the treatment of advanced gastric cancer | TA191 | | |
| Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer | TA192 | | |
| Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia | TA193 | | |
| Human growth hormone (somatropin) for the treatment of growth failure in children | TA188 | | |
| Improving outcomes for people with skin tumours including melanoma | CSG8 | | |
| Infliximab and adalimumab for the treatment of Crohn's disease | TA187 | | |
| Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes | TA47 | | |
| Donor milk banks: service operation | CG93 | | |
| Topotecan for the treatment of relapsed small-cell lung cancer | TA184 | | |
| Depression in adults with a chronic physical health problem: recognition and management | CG91 | | |
| Topotecan for the treatment of recurrent and stage IVB cervical cancer | TA183 | | |
| Guidance on the use of electroconvulsive therapy | TA59 | | |
| Sunitinib for the treatment of gastrointestinal stromal tumours | TA179 | | |
| Pemetrexed for the first-line treatment of non-small-cell lung cancer | TA181 | | |
| Etanercept and efalizumab for treating moderate to severe plaque psoriasis | TA103 | | |
| Alitretinoin for the treatment of severe chronic hand eczema | TA177 | | |
| Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma | TA178 | | |
| Tenofovir disoproxil for the treatment of chronic hepatitis B | TA173 | | |
| Rituximab for the first-line treatment of chronic lymphocytic leukaemia | TA174 | | |
| Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management | CG84 | | |
| Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery | TA170 | | |
| Rehabilitation after critical illness in adults | CG83 | | |
| Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma | TA169 | | |
| Amantadine, oseltamivir and zanamivir for the treatment of influenza | TA168 | | |
| Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence | CG76 | | |
| Borderline personality disorder: recognition and management | CG78 | | |
| Machine perfusion systems and cold static storage of kidneys from deceased donors | TA165 | | |
| Infliximab for acute exacerbations of ulcerative colitis | TA163 | | |
| Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin | TA159 | | |
| Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery | TA157 | | |
| Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza | TA158 | | |
| Routine antenatal anti-D prophylaxis for women who are rhesus D negative | TA156 | | |
| Entecavir for the treatment of chronic hepatitis B | TA153 | | |
| Telbivudine for the treatment of chronic hepatitis B | TA154 | | |
| Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus | TA151 | | |
| Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck | TA145 | | |
| Adalimumab for treating moderate to severe plaque psoriasis | TA146 | | |
| Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) | TA148 | | |
| Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) | TA149 | | |
| Structural neuroimaging in first-episode psychosis | TA136 | | |
| Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma | TA137 | | |
| Infliximab for treating moderate to severe plaque psoriasis | TA134 | | |
| Pemetrexed for the treatment of malignant pleural mesothelioma | TA135 | | |
| Bortezomib monotherapy for relapsed multiple myeloma | TA129 | | |
| Stapled haemorrhoidopexy for the treatment of haemorrhoids | TA128 | | |
| Pemetrexed for the treatment of non-small-cell lung cancer | TA124 | | |
| Drug misuse in over 16s: psychosocial interventions | CG51 | | |
| Acutely ill adults in hospital: recognising and responding to deterioration | CG50 | | |
| Drug misuse in over 16s: opioid detoxification | CG52 | | |
| Varenicline for smoking cessation | TA123 | | |
| Faecal incontinence in adults: management | CG49 | | |
| Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma | TA121 | | |
| Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia | TA119 | | |
| Methadone and buprenorphine for the management of opioid dependence | TA114 | | |
| Naltrexone for the management of opioid dependence | TA115 | | |
| Gemcitabine for the treatment of metastatic breast cancer | TA116 | | |
| Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy | TA117 | | |
| Laparoscopic surgery for colorectal cancer | TA105 | | |
| Improving outcomes for people with brain and other central nervous system tumours | CSG10 | | |
| Docetaxel for the treatment of hormone-refractory metastatic prostate cancer | TA101 | | |
| Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer | TA100 | | |
| Improving outcomes for people with sarcoma | CSG9 | | |
| Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B | TA96 | | |
| Obsessive-compulsive disorder and body dysmorphic disorder: treatment | CG31 | | |
| Improving outcomes in children and young people with cancer | CSG7 | | |
| HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) | TA92 | | |
| Guidance on the use of paclitaxel in the treatment of ovarian cancer | TA55 | | |
| Improving outcomes in head and neck cancers | CSG6 | | |
| Dental checks: intervals between oral health reviews | CG19 | | |
| Laparoscopic surgery for inguinal hernia repair | TA83 | | |
| Frequency of application of topical corticosteroids for atopic eczema | TA81 | | |
| Tacrolimus and pimecrolimus for atopic eczema | TA82 | | |
| Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding | TA78 | | |
| Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia | TA77 | | |
| Pre-hospital initiation of fluid replacement therapy in trauma | TA74 | | |
| Guidance on the use of liquid-based cytology for cervical screening | TA69 | | |
| Human growth hormone (somatropin) in adults with growth hormone deficiency | TA64 | | |
| Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer | TA61 | | |
| Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction | TA52 | | |
| Guidance on the use of ultrasound locating devices for placing central venous catheters | TA49 | | |
| Guidance on the use of trastuzumab for the treatment of advanced breast cancer | TA34 | | |
| Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia | TA29 | | |
| Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease | TA20 | | |
| Guidance on the extraction of wisdom teeth | TA1 | | |